Heparan sulfate (HS) proteoglycan chains are key components of the breast tumor microenvironment that critically influence the behavior of cancer cells. It is established that abnormal synthesis and processing of HS play a prominent role in tumorigenesis, albeit mechanisms remain mostly obscure. HS function is mainly controlled by sulfotransferases, and here we report a novel cellular and pathophysiological significance for the 3-O-sulfotransferase 3-OST3A (HS3ST3A), catalyzing the final maturation step of HS, in breast cancer. We show that 3-OST3A is epigenetically repressed in all breast cancer cell lines of a panel representative of distinct molecular subgroups, except in human epidermal growth factor receptor 2-positive (HER2+) sloan-kettering breast cancer (SKBR3) cells. Epigenetic mechanisms involved both DNA methylation and histone modifications, producing different repressive chromatin environments depending on the cell molecular signature. Gain and loss of function experiments by cDNA and siRNA transfection revealed profound effects of 3-OST3A expression on cell behavior including apoptosis, proliferation, response to trastuzumab in vitro and tumor growth in xenografted mice. 3-OST3A exerted dual activities acting as tumor-suppressor in lumA-michigan cancer foundation (MCF)-7 and triple negative-MD Anderson (MDA) metastatic breast (MB)-231 cells, or as an oncogenic factor in HER2+-SKBR3 cells. Mechanistically, fluorescence-resonance energy transfer-fluorescence-lifetime imaging microscopy experiments indicated that the effects of 3-OST3A in MCF-7 cells were mediated by altered interactions between HS and fibroblast growth factor-7 (FGF-7). Further, this interplay between HS and FGF-7 modulated downstream ERK, AKT and p38 cascades, suggesting that altering 3-O-sulfation affects FGFR2IIIb-mediated signaling. Corroborating our cellular data, a clinical study conducted in a cohort of breast cancer patients uncovered that, in HER2+ patients, high level expression of 3-OST3A in tumors was associated with reduced relapse-free survival. Our findings define 3-OST3A as a novel regulator of breast cancer pathogenicity, displaying tumor-suppressive or oncogenic activities in a cell-and tumor-dependent context, and demonstrate the clinical value of the HS-O-sulfotransferase 3-OST3A as a prognostic marker in HER2+ patients.
INTRODUCTION
Heparan sulfate proteoglycans (HSPG) are integral components of extracellular matrices and cell plasma membranes. They are key determinants of the relationships cells have with each other and with their microenvironment, and their role in cancer biology is increasingly recognized. 1 HS glycosaminoglycan chains of cell surface PG, strategically located at the cell-matrix interface, act as co-receptors for numerous signal transduction pathways. HS are composed of uronic acid and N-acetylglucosamine repeating disaccharide units covalently attached to the core protein of PG through a tetrasaccharide linkage region. 2 During biosynthesis, HS are subjected to marked structural modifications -mainly epimerization, N-deacetylation, N-and O-sulfation, catalyzed by numerous enzymes, including HS-O-sulfotransferases. 3, 4 The range of biological functions of HS ultimately depends on the fine structure of their polysaccharide chain. The 3-O-sulfotransferases (3-OST) form the largest multigene family of HS modifying enzymes with seven different isoforms, catalyzing O-sulfation at position 3 of glucosamine (GlcN) residues to produce at least two functionally distinct 3-O-sulfated motifs. Importantly, this relatively rare modification completes the fine-tuning of HSPG and is responsible for highlyspecific HS activities. 5 The best characterized is the anticoagulant property of the 3-O-sulfated anti-thrombin binding motif, primarily generated by the 3-OST1 isoform. Although it is mostly documented that 3-OST3A generates receptors for Herpes simplex virus type-1 (HSV-1) entry, 6 other likely biological functions, such as regulation of growth factors and their tyrosine kinase receptors signaling remain to be explored.
HSPG are critical effectors of several hallmarks of cancer biology. 7 In tumor cells, genes involved in the biosynthesis of HSPG are frequently dysregulated. The upregulation of cell-surface 1 HSPG glypican-1 and syndecan-1 has been described in malignant breast cancer tissue, 8 while depletion of the extracellular sulfatase Sulf-1 was reported. 9 Disruption of HS biosynthetic enzymes results in changes in HS fine structure that critically affect cell-matrix interactions, cell signaling and tumor cell behavior, including proliferation, adhesion, migration and apoptosis through interplay of complex mechanisms. 10 Recent studies highlight an aberrant modulation of 3-OST gene expression through epigenetic mechanisms in various tumors including the breast, lung, brain, pancreatic, skin and colorectal cancers, suggesting an important role in these pathological conditions. 11, 12 However, these reports reveal either anti-oncogenic or tumor-promoting effects, and the mechanisms and consequences of 3-OST dysregulation in the cancer process are thus not well understood. 13, 14 We recently showed that epigenetic repression of 3-OST genes in chondrosarcoma cells leads to altered HSPG sulfation, and demonstrated tumor-suppressive properties of 3-O-sulfation in chondrosarcoma cells. 15 Identification of the molecular mechanisms underlying the role of HS-modifying enzymes in breast cancer may open new windows for the design of personalized therapies to overcome drug failure and for the discovery of new biomarkers. Here, we demonstrate a critical role of 3-OST3A in specific breast cancer subtypes. We showed epigenetic repression of 3-OST3A in several breast cancer cell lines, and demonstrated its impact on cancer cell behavior by gain and loss of function approaches. Importantly, we examined the influence of 3-OST3A expression on clinical outcome in a cohort of breast cancer patients. Our study identifies the HS-sulfotransferase 3-OST3A as a novel tumor regulator exerting either tumor-suppressive or oncogenic properties in a cell-dependent context, and demonstrates its potential clinical value as a prognostic marker in human epidermal growth factor receptor 2-positive (HER2+) breast cancer patients enabling stratification of patients for treatment.
RESULTS

3-
OST3A is differentially repressed in breast cancer cell lines via epigenetic mechanisms Prompted by studies from us and others pointing to an epigenetic control of 3-OST genes, 11, 15 we determined whether 3-OST3A was regulated epigenetically in breast cancer cells. 3-OST3A expression analysis in a panel of cell lines representative of distinct molecular subgroups of breast cancer (luminal-A (lumA): ER+, PR+, HER2 − ; luminal-B (lumB): ER+, PR+, HER2+-; HER2+: ER − , PR− , HER2+; triple-negative (TN): ER − , PR − , HER2 − , 16 Supplementary Table S1) revealed very low mRNA level in BT-474, T-47D and MD Anderson (MDA)-derived cells, and reduced expression in lumAmichigan cancer foundation (MCF)-7 cells compared with the non-tumorigenic epithelial-derived MCF-10A cells (Figure 1a) . The highest expression level was for HER2+ sloan-kettering breast cancer (SKBR3) cells.
DNA methylation analysis of the 3-OST3A promoter CpG island (Supplementary Figure S1A) showed strong hypermethylation in T-47D and MDA-derived cells, while in MCF-7 cells, hypermethylation only occurred downstream from the TSS (Figure 1b) . In contrast, 3-OST3A was not subject to DNA methylation in SKBR3 and MCF-10A cells (Figure 1b and Supplementary S1B). We established further a link between 3-OST3A hypermethylation and gene expression by treating the MCF-7 and MDA-metastatic breast (MB)-231 cells with 5-aza-2'-deoxycytidine (Aza, DNAmethyltransferase (DNMT) inhibitor) and trichostatin A (TSA, histone deacetylase (HDAC) inhibitor). In MCF-7 cells, Aza and TSA alone markedly increased 3-OST3A mRNA level (Figure 1c) , while no additive effect was observed upon combined treatment. Conversely in MDA-MB-231 cells, neither Aza nor TSA independently produced a significant effect, whereas combined treatment increased expression, suggestive of a co-operative action between histone deacetylation and DNA methylation (Figure 1c) .
To provide insight into the differential regulation of 3-OST3A in MCF-7 and MDA-MB-231 cells, representative of the lumA and TN subtype, respectively, we analyzed several epigenetic marks at the 3-OST3A promoter. We first evaluated the abundance of DNMT3A and 3B isoforms, and of DNMT1 involved in de novo and maintenance of DNA methylation, respectively (Figure 2a) . We next examined several Polycomb group (PcG) proteins that form large complexes generally associated with CpG island promoters and cause closure of local chromatin mainly by affecting histone modifications. 17 We investigated here enhancer of zeste homolog 2 (EZH2) that trimethylates Lys27 of histone 3 (H3K27me3) and is associated with the suppressor of zeste 12 (SUZ12) protein to form part of Polycomb repressive complex PRC2. To further investigate the crosstalk between DNA methylation and histone modifications, the methyl-CpG-binding protein 2 (MeCP2) that recruits histone deacetylases (HDACs) to the methylated regions 18 as well as Sin3A that functions as a corepressor complex with HDACs and MeCP2 19 were investigated. In MCF-7 cells, enrichment in DNMT3B (Figure 2b ) was associated with a strong increase in the repressive H3K27me3, but not in the other repressive trimethylated Lys9 of histone 3 (H3K9me3, Figure 2c ) histone mark. As expected, a decrease in the active mark trimethylated Lys4 of histone 3 (H3K4me3) was observed compared with MCF-10A (Figure 2c) .
In MDA-MB-231, a strong increase in abundance of DNMT1 and DNMT3A was associated with the presence of repressive H3K9me3 and H3K27me3 and with the depletion of H3K4me3 (Figures 2b  and c) . As expected, in MCF-10A cells H3K4me3 was abundant and H3K9me3 and H3K27me3 absent (Figure 2c ). Interestingly, although 3-OST3A regulation in SKBR3 cells does not involve DNA methylation, ChIP analysis suggested that it could involve histone modifications (data not shown). The histone H3K27 methyltransferase EZH2 was abundantly associated with the 3-OST3A gene in MDA-MB-231, whereas it was less recruited in MCF-7 cells, while SUZ12 was present at low levels ( Figure 2d ). These data suggest that proteins of the PRC2 complex mediate 3-OST3A gene repression in combination with DNMT3B in MCF-7 cells, and with DNMT1 and 3A in MDA-MB-231. Investigation of the crosstalk between DNA methylation and histone modifications showed that in MCF-7 cells the recruitment of HDAC1 did not require MeCP2 (Figure 2e ), in agreement with the observation that Aza and TSA derepressed the promoter independently. Conversely in MDA-MB-231 cells, MeCP2, HDAC1 and Sin3A were enriched at the 3-OST3A locus (Figure 2e ). Such repressive environment might explain why treatment with both deacetylation and methylation inhibitors is required to reactivate 3-OST3A expression in the latter cells. The distinct repressive complexes in the two cell lines are schematically depicted in Figure 2f. 3-OST3A exerts tumor-suppressive or pro-oncogenic effects depending on tumor cell phenotype and influences response to trastuzumab Having demonstrated different expression level and epigenetic behavior in lumA-MCF-7, TN-MDA-MB-231 and HER2+-SKBR3 cells, we next interrogated the functional impact of 3-OST3A expression in these cell lines by gain and loss of function experiments. Overexpression moderately reduced cell growth rate in MCF-7 cells and completely inhibited cell proliferation in MDA-MB-231 cells (Figure 3a) . Importantly, in SKBR3 cells, 3-OST3A expression produced the opposite effect, enhancing proliferation, whereas its knockdown by siRNA transfection consistently reduced cell growth (Figure 3a) . These data emphasize the cell-context dependent outcome of HS 3-O-sulfation upon 3-OST3A overexpression or silencing, that we showed by performing immunofluorescence staining experiments using specific HS4C3 antibodies 20 (data not shown). A cornerstone of HER2 therapeutic strategies involves the use of a humanized monoclonal anti-HER2 antibody (trastuzumab) leading us to analyze the influence of 3-OST3A expression on HER2+-SKBR3 drug response. Significantly, trastuzumab exerted a stronger antiproliferative effect in 3-OST3A-expressing than in vector-transfected cells, whereas its influence was abrogated following 3-OST3A siRNA knockdown (Figure 3b ), indicating that 3-OST3A not only acts as a tumor regulator but also modulates anticancer drug sensitivity.
Analysis of apoptosis using annexin V staining showed that 3-OST3A expression was pro-apoptotic in MCF-7 cells (Figure 4a ), but not in MDA-MB-231 and SKBR3 cells (Supplementary Figure S2) . Further investigation of the cell survival mechanisms in MCF-7 RT-qPCR was performed using gene-specific primers, expression level was normalized to RP29, and mRNA level in breast cancer cell lines is expressed relative to MCF-10A control cells (set to 1). **Po0.01, ***P o0.001, n = 3. (b) The methylation profile of the proximal promoter region (5') and first exon (3') of 3-OST3A shows hypermethylation in all cell lines but SKBR3. The number of methylated and non-methylated sites in the regions of interest (shown in Supplementary Figure S1 ) is indicated by hatched and empty bars, respectively. Results are the mean from sequencing data of at least three independent clones. (c) Effect of the DNAmethyltransferase inhibitor Aza, and of the histone deacetylase inhibitor TSA on 3-OST3A mRNA expression level indicate epigenetic mechanisms involving DNA methylation and histone deacetylation. MCF-7 (left panel) or MDA-MB-231 cells (right panel) were treated with Aza or TSA alone, or with both drugs. RT-qPCR was performed as described in panel A. **P o0.01, ***P o0.001, n = 3. 3-OST3A affects FGF-7-HS interactions and regulates FGF-7 signaling HSPGs influence the tumor process by regulating the activity of a variety of signaling molecules, primarily fibroblast growth factors (FGFs). 21 FGF-7 (keratinocyte growth factor) acting on epithelial cells 22 is a potent mitogen for mammary glands, 23, 24 and induces proliferation and motility in breast cancer cells. 25 This led us to explore the influence of 3-OST3A expression on FGF-7-HS interactions and signaling. FGF-7 binding was analyzed by confocal microscopy, flow cytometry and, to directly assess FGF-7 and HS interactions, by fluorescence-resonance energy transfer (FRET)-fluorescence-lifetime imaging microscopy (FLIM) assays in MCF-7 cells compared with MCF-10A cells. siRNA transfected MCF-10A cells displayed a strong pericellular immunofluorescent staining pattern, consistent with enhanced FGF-7 The antiproliferative effect of trastuzumab was enhanced upon 3-OST3A expression, whereas it was suppressed in SKBR3-depleted cells. **P o0.01, ***P o0.001, n = 4.
binding, whereas FGF-7 staining was reduced in MCF-7 upon 3-OST3A expression (Figures 5a and b) . Quantitative flow cytometry clearly confirmed an increase in fluorescence signal associated with FGF-7 binding in siRNA transfected MCF-10A, and a decrease in 3-OST3A transfected MCF-7 cells (Figure 5c ). Figure S4) , a clear increase in emission intensity of HS-AlexaFluor 555 was observed in empty vector transfected MCF-7 cells compared with those transfected with 3-OST3A (Supplementary Figure S4A) . Lambda scan showed a significant FRET from FGF-7-AlexaFluor 488 to HS-AlexaFluor 555 in 3-OST3A: clinico-pathological impact in breast cancer X Mao et al cells that did not express 3-OST3A-HA (Supplementary Figure S4B) . FLIM analysis confirmed a greater distribution in favor of the FRET positive cell population (in green) in control cells, compared with 3-OST3A transfected cells (Figure 5d ). The average lifetime of AlexaFluor 488 was unchanged in cells expressing 3-OST3A-HA, but reduced in control and 3-OST3A-HA-negative cells ( Figure 5e , Table 1 ). These data indicate that binding of FGF-7 is HS-dependent, and that it is impaired upon 3-OST3A overexpression in MCF-7 cells, highlighting the potential impact of 3-O-sulfation on FGF-7-HS interactions.
In a FRET assay (Supplementary
We next examined whether impaired FGF-7-HS interactions mediated by 3-OST3A would affect FGF-7 downstream signaling pathways. FGF-7 activates the Ras-MAP kinase and PI3K-AKT cascades following binding to its receptor FGFR2IIIb, a splice variant of FGFR2 expressed in breast carcinoma cell lines. 26, 27 Indeed, phosphorylation of AKT was reduced upon FGF-7 treatment at low dose in 3-OST3A-transfected MCF-7 cells (Figure 5f ). Furthermore, ERK phosphorylation was strongly inhibited upon 3-OST3A transfection from 0.5 to 1 ng/ml (Figure 5g ), whereas phosphorylation of p38 was increased in response to FGF-7 treatment (Figure 5h ). In empty vector transfected MCF-7 cells, a slight increase in ERK phosphorylation was observed at the highest FGF-7 concentration and exposure time (Supplementary Figure S5A) , whereas, no variations in AKT and p38 phosphorylation occurred (Supplementary Figures S5B and C) . Our results suggest that inactivation of the FGF-7-induced ERK signaling pathway is involved in the antiproliferative effect of 3-OST3A in lumA-MCF-7 cells, and that inhibition of FGF-7-AKT, together with activation of FGF-7-p38 signaling, contributes to its pro-apoptotic effect (as represented Supplementary Figure S6 ).
3-OST3A is a prognostic marker in breast cancer patients To assess the clinical relevance of our experimental data, we analyzed 3-OST3A expression in a cohort of primary breast tumors. 28 The cohort was segregated into four subtypes that is, lumA, lumB, HER2+ and TN according to the pathological markers recommended by the St Gallen breast cancer consensus guidelines 16 (Supplementary Table S2 ). Consistent with other clinical studies, TN and HER2+ breast cancers were the most aggressive breast cancers (Supplementary Figure S8A) . All tumors expressed 3-OST3A (Figure 6a ) and Kruskal-Wallis analysis indicated that the level of 3-OST3A expression was associated with the breast cancer subtype (P o0.017). Importantly, 3-OST3A expression was significantly lower in lumA-tumors compared with other breast cancer subtypes (Mann-Whitney, Po0.042). This observation suggested that a low expression of 3-OST3A contributes to the cancer process in lumA tumors, as corroborated by the tumor-suppressive effect mediated by 3-OST3A overexpression in MCF-7 cells (shown Figures 3a and 4a) . On the other hand, 3-OST3A expression was significantly higher in HER2+ tumors (Mann-Whitney, Po0.008), suggesting that in this subtype, elevated 3-OST3A would favor breast cancer formation and progression, in accordance with its oncogenic properties in SKBR3 cells (shown Figure 3a) .
We next investigated the relationship between 3-OST3A expression and HER2+ patient outcome. The optimal cut-off for HER2+ breast tumors was determined by receiver operating characteristic curves 29, 30 (Supplementary Figure S7) . Importantly, we showed using univariate analysis that 3-OST3A expression was significantly associated with cancer progression (CP) (Fisher exact t-test; P ⩽ 0.004) and death (P ⩽ 0.046) in HER2+ breast tumors (Supplementary Table S3 ). This was confirmed by Kaplan-Meier log-rank analyses (CP, χ 2 = 7.221, 1 df, P ⩽ 0.007; death, χ 2 = 3.686, 1 df, P ⩽ 0.055, Figure 6b) .
In addition to 3-OST3A expression (3ost), tumor size (S) and lymph node metastasis (LN, absence or presence) were independently associated with CP in HER2+ breast cancers (Supplementary Figure S8B and C, Supplementary Table S4-S6) . We then formed a binary variable (3ost, S, LN) that was positive only when the HER2+ patients had a 3-OST3A positive tumor of a diameter larger than 20 mm and at least one lymph node metastasis (Figure 6c ). Multivariate Cox's regression analysis determined the interdependence degree between these three parameters and confirmed that the combined variable (3ost, S, LN) stood out as an independent significant predictor of cancer recurrence and death ( Table 2 ). This positive variable (3ost, S, LN) enhanced 27-fold the risk of recurrence (Hazard ratio (HR), 27.3; 95% Confidence Interval (CI), 3.6 to 207.7). The Omnibus test indicated that the number of HER2+ breast tumors is sufficient to support this conclusion ( Table 2 ). The cox's regression analysis was further confirmed by Kaplan-Meier log-rank analyses (CP: χ 2 = 23.233, 1 df, Po2.10
, death: χ 2 = 14.354, 1 df, Po2.10
, Figure 6c ) indicating that the combined variable (3ost, S, LN) separated two subtypes of HER2+ breast cancer patients with opposite clinical outcome.
The HER2+ breast cancer patients positive for (3ost, S, LN) represented 43% of total HER2+ patients and among these patients, 71% (15/21) suffered from recurrence ( Figure 6c ) compared with 44% (16/36) when considering 3-OST3A expression only (Figure 6b ), thus providing a discriminating biomarker for clinicians. Considering the combined variable allowed the identification of 93% (15/16) of patients in whom cancer recurred or who died, while the HER2+ patients negative for (3ost, S, LN) had no recurrence over 15 years. Our results suggest that the current treatment of HER2+ patients is efficient in 96% (27/28) of the (3ost, S, LN) negative patients, while the HER2+ breast cancer patients positive for (3ost, S, LN) would benefit from additional or alternative treatment such as trastuzumab.
DISCUSSION
This study reports for the first time the molecular, functional and clinical role of the HS-sulfotransferase 3-OST3A, a key enzyme controlling the tumor microenvironment, in breast cancer. A main result of our work is the unequivocal demonstration that 3-OST3A can display either oncogenic or tumor-suppressive effects depending on the cell and tumor phenotype. This detailed analysis clarifies conflicting literature that reports contrasting effects of 3-OSTs expression on tumorigenesis in different types of cancer and cell 
models.
13,14 Importantly, the clinical study performed here shows that 3-OST3A is differentially expressed in distinct subtypes of tumors, corroborating our in vitro data, and establishes the prognostic value of 3-OST3A as a novel marker in HER2+ breast cancer patients.
Previous reports including ours have documented the epigenetic repression of several 3-OST genes in tumor cells. 11, 15, 31 Our study shows that 3-OST3A was repressed and subjected to hypermethylation in all breast cancer cell lines tested except in HER2+-SKBR3 cells in which, consistently, it was expressed at relatively high level. Further analysis of the chromatin interactors at the 3-OST3A promoter showed that the epigenetic regulation not only depends upon DNA methylation, but also on repressive histone marks, and involves the recruitment of PcG proteins. We describe here for the first time a fine interplay between DNA methylation, histone modifications and epigenetic regulators of the PRC2 complex controlling 3-OST3A expression in a cell-context dependent manner. In lumA-MCF-7 cells, DNMT3B and the EZH2 subunit of the PRC2 complex involved in writing the repressive H3K27me3 mark form a chromatin environment that moderately repressed transcriptional activity. In MDA-MB-231 cells, we propose a scenario at the 3-OST3A promoter, in which the methylated DNA reader MeCP2 is associated with a deacetylase complex formed by Sin3A, HDAC1 and possibly H3K9 methyltransferases. 18 Altogether the chromatin interactors DNMT1, 3A, PcG proteins and the histone marks H3K27me3 and H3K9me3 produce gene silencing in these cells. Our demonstration of the HS-sulfotransferase 3-OST3A gene methylation and histone modification is in line with previous findings indicating that epigenetic dysregulation is an important feature of breast cancer pathobiology and that it depends upon the tumor signature. 32 Our results validate the potential value of epigenetic therapies targeting 3-OST3A together with other silenced critical genes such as those coding for the Ras interacting protein RASSF1A, 33 the estrogen receptor α 34 and the retinoic acid receptor α 35 in TN breast cancers. Altogether, our findings support the attractive idea that the HS-modifying 3-OST3A sulfotransferase enzyme participates to the matrix-cell dialog through epigenetic mechanisms.
FGFs, a significant group of HS ligands, use HSPG as co-receptors to bind specific tyrosine kinase receptors promoting signal transduction, and FGF signaling is deregulated in many cancer types. 36 We thus hypothesized that 3-OST3A epigenetic regulation may alter breast cancer cell phenotype through modulation of FGF-dependent intracellular signaling. FGF-7 secreted by stromal mesenchymal cells acts on epithelial cells, where it associates with the FGFR2IIIb receptor. Alteration of the FGF-7-FGFR2IIIb signaling axis contributes to the oncogenic process by activating intracellular kinase cascades including ERK-dependent proliferation and AKT-mediated cell survival in breast cancer cells, 37 and anti-FGFR2IIIb antibodies offer a new therapeutic option. 38 Since FGF-7 is one of the most structurally specific FGFs with respect to its requirement for a 3-O-sulfated motif to coordinate ligand-receptor complex assembly, 39, 40 we investigated whether 3-OST3A expression may regulate its signaling pathway to trigger the tumor-suppressive effect observed in the lumA-MCF-7 cells. Supporting this assumption, our data show that reinstating 3-OST3A expression in these cells: (i) impaired interactions between FGF-7 and HS chains, (ii) inhibited proliferative signals via ERK dephosphorylation and (iii) boosted apoptotic signals via AKT dephosphorylation and p38 phosphorylation. Our observations are of particular interest since FGF-7 plays a critical role both in mammary gland development and breast cancer onset and progression. 41 Since 3-O-sulfation is an important modification of HS for HS-FGF-7-FGFR2IIIb complex formation, 42 our data support the idea that this modification might contribute to the anti-oncogenic properties of 3-OST3A in lumA cells. However, it is of note that the mechanisms underlying impaired FGF-7 binding in MCF-7 cells upon 3-OST3A expression are not fully understood. We ruled out the possibility that 3-OST3A would reduce FGFR2IIIb expression (data not shown). On the other hand, according to several reports, 43 it is hypothesized that 3-O-sulfated HS binding may precede and prevent FGF-7 interactions with its FGFR2IIIb receptor. Another possibility is that altered activation of fibroblast growth factor receptor substrate 2 (FRS2α) would trigger internalization and degradation of FGFR2IIIb thus contributing to attenuate FGF-7 binding and signaling seen in our experiments upon 3-OST3A expression. These options are currently under investigation in our laboratory.
Since the effects triggered by 3-OST3A expression in breast cancer cell lines depended on their molecular signature, a major aim of the present study was to evaluate the clinico-pathological impact of 3-OST3A expression in breast cancer. We provided insight into this key issue by conducting a clinical study in a cohort of breast cancer patients followed over a 15-year period. The low expression detected in lumA tumors suggests that 3-OST3A might inhibit cancer formation and progression and is consistent with a tumor-suppressive effect in this subtype of malignancies. This assumption is supported by our experimental data showing a pro-apoptotic and anti-proliferative effect triggered by 3-OST3A expression in MCF-7 cells, associated with tumor growth retardation in xenografted mice.
A key finding is that, in HER2+ subtype breast cancer patients, high 3-OST3A expression is associated with reduced survival. The SKBR3 cell model harboring this molecular signature allowed us to explore the mechanisms underlying our clinical observations. Consistently, we showed that 3-OST3A overexpression in SKBR3 cells promotes proliferation, whereas its silencing results in the reverse effect. Furthermore, 3-OST3A expression enhanced the antiproliferative effect of trastuzumab whereas knocking-down expression arrested it. This result has two important outcomes. First, it suggests that 3-OST3A-mediated HS modification alters the HER2 receptor-mediated signaling pathway, an assumption that is currently under investigation. Second, it reveals a novel and potentially clinically important effect of 3-OST3A on sensitivity to the therapeutic anti-HER2 antibody trastuzumab. Identifying the HER2+ breast cancer patients who might benefit from extended adjuvant therapy represents a long-standing conundrum. In our cohort, about 40% of HER2+ breast cancer patients given chemotherapy (5-fluorouracil, epirubicin (doxorubicin) and campthothecin) suffered from cancer progression, a poor outcome highlighting a currently unmet clinical need. This phenomenon, strongly supported by the data presented here, could therefore facilitate the stratification of two populations of HER2+ breast cancer patients; one 3-OST3A positive population with at least one lymph node metastasis and a tumor diameter 421 mm who are much more likely (71% chance) to suffer from cancer recurrence and death, and thus would clearly benefit from alternative therapy such as trastuzumab, while the 3-OST3A negative population has a much better prognosis with lack of recurrence over 15 years.
In conclusion, we show that the sulfotransferase 3-OST3A, involved in the final step of HS processing, is a key regulator of tumor cell behavior and anticancer drug response, and that its oncogenic or tumor-suppressive effects are cell-and tumor- Po0.05 vs HA − , n = 3. Statistical analysis was performed using one-way ANOVA with Tukey's post-hoc test.
3-OST3A: clinico-pathological impact in breast cancer X Mao et al signature dependent. The finding that 3-OST3A expression correlates with cancer progression in HER2+ patients highlights its clinical significance for guiding therapeutic options in breast cancer treatment. 
MATERIALS AND METHODS
RT-qPCR analysis
Total RNA was extracted and purified using the RNeasy Mini kit (Qiagen) for cultured cells and the QIAzol Lysis reagent (Qiagen) for tumor samples. mRNA level was quantified by the 2-ΔΔC t method using the primers listed in Supplementary Table S9. CpG island identification, methylation analysis and chromatin immunoprecipitation (ChIP) assay Genomic DNA was purified using the GenomicPrepDNA isolation kit (GE Healthcare, Buckinghamshire, UK). The presence of a canonical CpG island in the proximal promoter region (5') and first exon (3') of 3-OST3A gene was determined using the MethPrimer software (Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences, China). The methylation status of two regions was analyzed by bisulfite sequencing 15 using sense and antisense primers for nested-PCR (Supplementary Table S10 ). PCR products subcloned into TOPO-TA vector (Invitrogen, Carlsbad, CA, USA) were sequenced in at least three clones. ChIP assay was performed using the Low Cell# ChIP kit (Diagenode, Liège, Belgium) using antibodies and PCR primers described in Supplementary Tables S11 and S12, respectively.
Protein analysis
Immunoblot following SDS-PAGE analysis of cell lysate proteins was performed using the primary and secondary antibodies listed in Supplementary Table S7. FGF-7 cell-surface binding assays Cells cultured in Lab-Tek chambers (Thermo-Scientific) or 6-well plates were serum-starved and incubated with recombinant human FGF-7 (0.5 ng/ml) for 30 min. Cells were immunostained for FGF-7 and HS expression using antibodies (Supplementary Table S7 ) prior to confocal laser scanning microscopy. Alternatively, following immunostaining, cells were fixed in 4% (w/v) paraformaldehyde prior to flow cytometry (Gallios, Beckman Coulter, Beckman Coulter Genomics, Essex, UK).
FLIM-based FRET Assay
For the image series and spectra measurements, a Leica TCS SP5-X-AOBS microscope equipped with an acousto-optical beamsplitter and WLL lasers was used with a × 40/0.8 water immersion objective. Temporal histogram depicting the AlexaFluor 488 fluorescence lifetime was obtained by a biexponential fit of the fluorescence decay. The decay analysis by timecorrelated single photon counting was performed using the SPCImage software (Becker & Hickl GmbH, Berlin, Germany).
Cell apoptosis assays
After transient transfection with empty vector or with 3-OST3A-HA cDNA and with siRNA control or siRNA 3-OST3A in the case of SKBR3 cells for 48 h, cells were stained with AlexaFluor 488-conjugated annexin V and propidium iodide (PI) dyes (Invitrogen). The externalization of phosphatidylserine (PS) and the permeability to PI were evaluated by flow cytometry. A TUNEL test was also performed on MCF-7 cells transfected with empty vector or with 3-OST3A-HA cDNA.
Cell proliferation assay
Twenty four hours after transfection with 3-OST3A-HA cDNA, and with siRNA 3-OST3A and corresponding controls, MCF-7, MDA-MB-231 and SKBR3 cells were harvested each day during a 4-day period, and cell proliferation was evaluated by measuring DNA content. Cell proliferation was also assessed 2 days following transient transfection in SKBR3 cells treated with 0, 20 and 40 μg/ml trastuzumab kindly provided by Dr. Catherine Vallance (Institut de Cancérologie de Lorraine, Vandoeuvreles-Nancy, France).
In vivo mouse xenograft tumor model
Experiments were performed in 6-week-old female severe combined immunodeficient mice. MCF-7 cells stably expressing 3-OST3A-HA or transfected with pcDNA empty vector were subcutaneously implanted into the animals. 5 × 10 6 cells were injected into each mouse (four mice/group for each independent experiment). The tumor growth was assessed weekly using a Vernier caliper. The experiment was conducted twice using two different engineered MCF-7 cell lines denominated 3-OST3A-A and -B, and pcDNA-A and -B, respectively.
Breast tumor sample analyses 3-OST3A mRNA expression was analyzed in a cohort of 117 primary breast tumors collected at Ninewells Hospital, Dundee, UK from Caucasian women with no previous treatment or operation (Tayside Tissue Bank (TTB), Dundee, UK). Informed consent was obtained from all patients and ethical approval was received from TTB (REC reference: 07/S1402/90) under delegated authority from the Local Research Ethics Committee. Breast cancer overall survival (overall survival) and breast cancer-specific disease free survival (disease free survival or cancer recurrence) were considered. Abbreviations: HR, hazard ratio; CI, confidence interval. Number of HER2+ patients, 49. The clinico-pathological parameters were: presence of lymph node metastasis (LN), tumor size (S), 3-OST3A (3ost) and the combined binary variable (3ost, S, LN).
3-OST3A: clinico-pathological impact in breast cancer X Mao et al Non-breast cancer deaths (women died from other causes than breast cancer) were censored. The characterization of classical molecular markers was conducted as previously described. 45 Histological tumor grade was according to Bloom et al., 46 ER status according to Quickscore method 47 and HER2+ scoring according to Purdie et al.
48
Statistical analysis
Data were analyzed using the Prism software (GraphPad, San Diego, CA) and are expressed as mean ± s.e.m. of two replicates in at least three independent experiments. One-way ANOVA and Tukey's post-hoc test were used for analysis of data from cell proliferation and FLIM assays. Two-way ANOVA and Bonferroni post-hoc tests were used to calculate differences in tumor growth. Paired Student's t-test was used to calculate P-values for all other experiments. P-value o0.05 was considered significant. Statistical univariate analyses (Kaplan-Meier and Log Rank test) of clinical data were performed using the SPSS software (SPSS, version 21.0, IBM Corp., Armonk, NY, USA) followed by multivariate analyses of Cox's proportional hazards regression model (CR) with associated Hazard Ratios (HR) utilizing the backwards step-wise elimination method.
Experimental procedures are detailed in the Supplementary Materials and Methods section.
